References:
1. Saypha MaglQ. Instructions for Use. Croma-Pharma GmbH; 2025.
2. Konstantin F, Downie J, Gold M, Joseph J, Green J, Fabi S, Bank D, Cohen JL, Shamban A. Weiss R, Krames-Juerss A. Monheit G. Multicenter, Randomized Split-Face Trial of a Crosslinked Hyaluronic Acid Filler With Lidocaine for Nasolabial Fold Correction. Aesthet Surg J. 2025 Aug l:sjafl37. 3. Data on file. Clinical Study Report. Croma-Pharma GmbH; 2025.

Important Safety Information
Saypha® MagIQ™ is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.

Do not use if you have severe allergies that have required in-hospital treatment, are allergic to lidocaine or gram-positive bacterial proteins used to make hyaluronic acid, prone to bleeding, or have a bleeding disorder.

The safety of use while pregnant or breastfeeding has not been studied.

Tell your doctor if you are planning other cosmetic treatments (such as lasers and chemical peels) as there is a possible risk of inflammation at the injection site.

The most common side effects include swelling, redness, pain, bruising, headache, tenderness, lump formation, itching at the injection site, and impaired hand function.

Tell your doctor if you’re taking medications that lower your body’s immune response or affect bleeding, such as aspirin or warfarin, these medications may increase the risk of bruising or bleeding at the gel injection site. Use at the site of skin sores, pimples, rashes, hives, cysts, or infection should be postponed until healing is complete.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers, and cases have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.

Serious but rare side effects include delayed-onset infections, recurrence of herpetic eruptions, superficial necrosis, and scarring at the injection site. The risk of unintentional injection into a blood vessel is small but can occur and could result in serious complications, which may be permanent including, vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. As with all skin injection procedures, there is a risk of infection.

Saypha® MagIQ™ is only available through a licensed practitioner. To learn more about serious but rare side effects and Complete Instructions for Use are available at www.obagi.com/saypha.
© 2026 Obagi Cosmeceuticals LLC. All rights reserved.
OBG.023.USA.26

Saypha® is a registered trademark of Croma-Pharma GmbH used under license. All other products/brand names, whether designated by notice or not (©/™), are trademarks of Obagi Cosmeceuticals LLC and/or its affiliates